Molecular classification and identification of an aggressive signature in low‐grade B‐cell lymphomas

Non-follicular low-grade B-cell lymphomas (LGBCL) are biologically diverse entities that share clinical and histologic features that make definitive pathologic categorization challenging. While most patients with LGBCL have an indolent course, some experience aggressive disease, highlighting additional heterogeneity across these subtypes. To investigate the potential for shared biology across subtypes, we performed RNA sequencing and applied machine learning approaches that identified five clusters of patients that grouped independently of subtype. One cluster was characterized by inferior outcome, upregulation of cell cycle genes, and increased tumor immune cell content. Integration of whole exome sequencing identified novel LGBCL mutations and enrichment of TNFAIP3 and BCL2 alterations in the poor survival cluster. Building on this, we further refined a transcriptomic signature associated with early clinical failure in two independent cohorts. Taken together, this study identifies unique clusters of LGBCL defined by novel gene expression signatures and immune profiles associated with outcome across diagnostic subtypes.

[1]  A. López-Guillermo,et al.  Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. , 2021, Blood.

[2]  K. Basso,et al.  Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma , 2021, Proceedings of the National Academy of Sciences.

[3]  Jaak Vilo,et al.  gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler , 2020, F1000Research.

[4]  M. Lim,et al.  Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma , 2020, Cancers.

[5]  Christine E. Cutucache,et al.  Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential , 2020, Frontiers in Oncology.

[6]  R. Gascoyne,et al.  Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses , 2019, Haematologica.

[7]  F. Merli,et al.  Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study. , 2019, Blood.

[8]  J. Cerhan,et al.  The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas , 2019, American journal of hematology.

[9]  I. Lossos,et al.  Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Arul M. Chinnaiyan,et al.  Cancer transcriptome profiling at the juncture of clinical translation , 2017, Nature Reviews Genetics.

[11]  J. Cerhan,et al.  Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. , 2017, International journal of epidemiology.

[12]  J. Ochando,et al.  T follicular helper cells: a potential therapeutic target in follicular lymphoma , 2017, Oncotarget.

[13]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[14]  W. Wilson,et al.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies , 2016, Haematologica.

[15]  Paolo Vineis,et al.  A genome-wide association study of marginal zone lymphoma shows association to the HLA region , 2015, Nature Communications.

[16]  J. Martinez-Climent,et al.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype , 2014, Leukemia.

[17]  R. Gascoyne,et al.  The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.

[18]  M. Piris,et al.  Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling , 2013, Modern Pathology.

[19]  Ahmet Dogan,et al.  An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma , 2012, PloS one.

[20]  S. Pileri,et al.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development , 2012, The Journal of experimental medicine.

[21]  I. Lossos,et al.  Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities , 2012, Modern Pathology.

[22]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[23]  A. Dogan,et al.  The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma , 2008, Leukemia.